PORTLAND, Ore., Nov. 22, 2019 (SEND2PRESS NEWSWIRE) — Paragon Gives, a Paragon BioTeck, Inc. initiative, announces their annual holiday event, “A Night to Remember,” for the children and families of Eugene Pearl Buck Preschool and Family Supports Program. “A Night to Remember” is a fun and festive holiday event with this year’s theme being a […]
PORTLAND, Ore., Nov. 19, 2019 (SEND2PRESS NEWSWIRE) — Paragon Gives, a Paragon BioTeck, Inc. initiative, is excited to announce a call for applications for the 2020 Koch Kellan Scholarship worth $10,000. This annual scholarship is awarded to one (1) outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.
PORTLAND, Ore., May 6, 2019 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., an ophthalmic pharmaceutical and medical device company, announced today that Mohima Sanyal has been named its 2019 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to elevating the standard of eye […]
PORTLAND, Ore., Nov. 27, 2018 (SEND2PRESS NEWSWIRE) — Paragon BioTeck announces holiday event, “A Night to Remember,” scheduled Friday, Dec. 7, 2018 from 5:30 – 8 p.m. in Eugene, Ore. The event delivers a magical night of holiday sights and sounds for the families of Pearl Buck Preschool.
PORTLAND, Ore., April 13, 2018 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., an ophthalmic pharmaceutical and medical device company, announced today that Alejandro Arboleda has been named its 2018 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to elevating the standard of eye […]
PORTLAND, Ore., Oct. 2, 2017 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or […]
PORTLAND, Ore., April 12, 2017 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., an ophthalmic pharmaceutical and device company, announced today that Xinxin Zhang has been named its 2017 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research […]
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. (Paragon), announces a monumental ruling handed down by the United States Patent and Trademark Office affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization […]
PORTLAND, Ore., Sept. 1, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the […]
PORTLAND, Ore., April 18, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., announced today that Hasenin Al-khersan has been named its 2016 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology.
PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company’s successful implementation of an effective quality management system.
PORTLAND, Ore., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an […]
PORTLAND, Ore., Nov. 17, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug. CE mark approval is recognized and associated […]
PORTLAND, Ore., Oct. 16, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announces that it will be formally launching its corporate citizenship initiative coined, Paragon Gives. On Sunday October 19, 2014, Paragon BioTeck, will kick off its newly […]
PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.
PORTLAND, Ore., June 25, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug.
PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.
PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.
PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) — Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products […]
PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.
MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.
